[
  {
    "ts": null,
    "headline": "Biotech Is Booming, and This Undervalued REIT Stands to Gain",
    "summary": "While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences.  Global biotech spending is projected to triple from roughly $1.7 trillion in 2025 to more than $5 trillion by 2034.  All that R&D cash needs purpose‑built laboratory space.",
    "url": "https://finnhub.io/api/news?id=69f44bc81dd3d18f79ecbbcdcc74636a38f005712eb2495255fea43e8607b837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753479360,
      "headline": "Biotech Is Booming, and This Undervalued REIT Stands to Gain",
      "id": 136095093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences.  Global biotech spending is projected to triple from roughly $1.7 trillion in 2025 to more than $5 trillion by 2034.  All that R&D cash needs purpose‑built laboratory space.",
      "url": "https://finnhub.io/api/news?id=69f44bc81dd3d18f79ecbbcdcc74636a38f005712eb2495255fea43e8607b837"
    }
  },
  {
    "ts": null,
    "headline": "Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs",
    "summary": "(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Most Read from BloombergTrump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in USThe High Costs of Trump’s ‘Big Beautiful’ New Car Loan DeductionCan This Bridge Ease the Troubled US-Canadian Relationship?Trump Administration Sues NYC Over Sanctuary City PolicyOn Friday, a group o",
    "url": "https://finnhub.io/api/news?id=cf6877a18277eefd7a1fc19ee9c34328b531714d7a58ebbdf3ac89b440eeb5ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753478268,
      "headline": "Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs",
      "id": 136101663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Most Read from BloombergTrump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in USThe High Costs of Trump’s ‘Big Beautiful’ New Car Loan DeductionCan This Bridge Ease the Troubled US-Canadian Relationship?Trump Administration Sues NYC Over Sanctuary City PolicyOn Friday, a group o",
      "url": "https://finnhub.io/api/news?id=cf6877a18277eefd7a1fc19ee9c34328b531714d7a58ebbdf3ac89b440eeb5ee"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Growth Fund Q2 2025 Commentary",
    "summary": "The Fundâs more diversified and defensive exposure compared to our concentrated benchmark reversed from a tailwind in the first quarter to a headwind in the second.",
    "url": "https://finnhub.io/api/news?id=28089d970b91f01c3a40f490653f424ec420999c6adb69eb8bbbd034fb009604",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753451400,
      "headline": "ClearBridge Large Cap Growth Fund Q2 2025 Commentary",
      "id": 136090262,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215528561/image_2215528561.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Fundâs more diversified and defensive exposure compared to our concentrated benchmark reversed from a tailwind in the first quarter to a headwind in the second.",
      "url": "https://finnhub.io/api/news?id=28089d970b91f01c3a40f490653f424ec420999c6adb69eb8bbbd034fb009604"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=1699b2b09dde54af9be4c2837f32c9eae0e5bbf1d4571f894054378db23902f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753448405,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136088543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=1699b2b09dde54af9be4c2837f32c9eae0e5bbf1d4571f894054378db23902f0"
    }
  },
  {
    "ts": null,
    "headline": "Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.",
    "url": "https://finnhub.io/api/news?id=45a112bcc270a39d8176b8e4dc3ba23e22aefaaa2f6a1278b5f0f67d67ea0fe7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753447740,
      "headline": "Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk",
      "id": 136088544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.",
      "url": "https://finnhub.io/api/news?id=45a112bcc270a39d8176b8e4dc3ba23e22aefaaa2f6a1278b5f0f67d67ea0fe7"
    }
  },
  {
    "ts": null,
    "headline": "In reversal, European regulators take positive view on Lilly Alzheimer’s drug",
    "summary": "Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug, Kisunla, one step closer to European market entry.",
    "url": "https://finnhub.io/api/news?id=8f98f1f7acc4bfa95e8be7a15123cbb57cfa4e38b867136c152288c72daf656d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753440120,
      "headline": "In reversal, European regulators take positive view on Lilly Alzheimer’s drug",
      "id": 136088545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug, Kisunla, one step closer to European market entry.",
      "url": "https://finnhub.io/api/news?id=8f98f1f7acc4bfa95e8be7a15123cbb57cfa4e38b867136c152288c72daf656d"
    }
  },
  {
    "ts": null,
    "headline": "Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers. The European Commission is expected to make a regulatory decision on donanemab in the coming months.",
    "url": "https://finnhub.io/api/news?id=015ef6143d59b72925c757b99b912708a7139b60122bc4ab6ca2c09c9f65e4dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753439220,
      "headline": "Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease",
      "id": 136084779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers. The European Commission is expected to make a regulatory decision on donanemab in the coming months.",
      "url": "https://finnhub.io/api/news?id=015ef6143d59b72925c757b99b912708a7139b60122bc4ab6ca2c09c9f65e4dd"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Q2: Confidently Continuing The Recovery",
    "summary": "Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX stock now.",
    "url": "https://finnhub.io/api/news?id=67ba08ae27cfc258522fa9f53ee8c42d7247f2dec8864a819ba0e01adbc1c2a7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753438500,
      "headline": "Viking Therapeutics Q2: Confidently Continuing The Recovery",
      "id": 136087868,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162809200/image_2162809200.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX stock now.",
      "url": "https://finnhub.io/api/news?id=67ba08ae27cfc258522fa9f53ee8c42d7247f2dec8864a819ba0e01adbc1c2a7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Wins CHMP Backing of Kisunla Alzheimer's Drug",
    "summary": "Eli Lilly Wins CHMP Backing of Kisunla Alzheimer's Drug",
    "url": "https://finnhub.io/api/news?id=2a3e846516051223cc5ad0774b73daed528cfec098dc5dbe324ddc646e0c93f0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753426740,
      "headline": "Eli Lilly Wins CHMP Backing of Kisunla Alzheimer's Drug",
      "id": 136109920,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Wins CHMP Backing of Kisunla Alzheimer's Drug",
      "url": "https://finnhub.io/api/news?id=2a3e846516051223cc5ad0774b73daed528cfec098dc5dbe324ddc646e0c93f0"
    }
  }
]